B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Purpose B cell-activating factor (BAFF) is expressed in adipocytes and affects lipogenesis and insulin sensitivity. In addition, the BAFF receptor is expressed in visceral adipose tissue and liver. The aim of this study was to analyze serum BAFF levels in patients with nonalcoholic steatohepatitis (NASH) and simple steatosis (SS) and to compare their respective clinical and histological findings.Methods A total of 96 patients with nonalcoholic fatty liver disease (20 with SS and 76 with NASH) were enrolled and their serum BAFF levels were analyzed. Comprehensive blood chemistry analysis and histological examination of liver samples were also conducted.Results Serum BAFF levels were higher in patients with NASH than in those with SS (p = 0.016). NASH patients with ballooning hepatocytes and advanced fibrosis had higher levels of BAFF in sera (p = 0.016 and p = 0.006, respectively). In addition, the prevalence of NASH increased significantly as the serum BAFF level increased (p = 0.004). Higher serum BAFF levels were found to be an independent risk factor for development of NASH (OR 1.003, 95% CI 1.0003-1.006; p = 0.047).Conclusions Nonalcoholic steatohepatitis patients had higher levels of serum BAFF than patients with SS, and higher levels were associated with the presence of hepatocyte ballooning and advanced fibrosis. The serum BAFF level may be a useful tool for distinguishing NASH from SS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Soluble markers related to B cell survival and activity including BAFF and IgG increase with worsening NASH severity, but the mechanisms by which B cells contribute to disease have not been characterized (142, 143).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [142]
In the citing paper
“Compared with subjects with simple steatosis, NASH patients have higher BAFF serum levels, which are positively correlated with hepatocyte ballooning and liver fibrosis.( 61 )”
From The Emerging Role of B Cells in the Pathogenesis of NAFLD (2021) · cites this paper as [61]
Citations
Cites
1 retracted
RETRACTED ARTICLE: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL
Litinskiy, M. B., Nardelli, B., Hilbert, D. M., He, B., Schaffer, A., Casali, P., & Cerutti, A. (2002) · Nature Immunology · doi:10.1038/ni829 · Cited by 1,252
RetractedDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“[30] was recorded as the unweighted sum of the scores for steatosis (0–3), lobular inflammation (0–3), and ballooning degeneration (0–2).”
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 2×
“perisinusoidal fibrosis; stage 2, zone 3 perisinusoidal fibrosis with portal fibrosis; stage 3, zone 3 perisinusoidal fibrosis and portal fibrosis with bridging fibrosis; and stage 4, cirrhosis [31].”
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“NASH was defined as a combination of steatosis, lobular inflammation, and ballooning degeneration with or without perisinusoidal/pericellular fibrosis [7, 8].”
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,385
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“Ballooned hepatocytes are caused by lipotoxicity and oxidant stress [40]; fibrosis is associated with the activation of hepatic stellate cells [41].”
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Splanchnic lipolysis in human obesity
Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D., & Jensen, M. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21047 · Cited by 933
The natural history of nonalcoholic fatty liver: A follow-up study
Teli, M. R., James, O. F. W., Burt, A. D., Bennett, M. K., & Day, C. P. (1995) · Hepatology · doi:10.1002/hep.1840220616 · Cited by 925
Wigg, A. J., Roberts-Thomson, I. C., Dymock, R. B., McCarthy, P. J., Grose, R. H., & Cummins, A. G. (2001) · Gut · doi:10.1136/gut.48.2.206 · Cited by 840
Inflammatory mechanisms in the regulation of insulin resistance
Tilg, H., & Moschen, A. R. (2008) · Molecular Medicine · doi:10.2119/2007-00119.tilg · Cited by 779
Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., & Younossi, Z. M. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.11.005 · Cited by 729
Synthesis and release of B-lymphocyte stimulator from myeloid cells
Nardelli, B., Belvedere, O., Roschke, V., Moore, P. A., Olsen, H. S., Migone, T. S., Sosnovtseva, S., Carrell, J. A., Feng, P., Giri, J. G., et al. (2001) · Blood · doi:10.1182/blood.v97.1.198 · Cited by 576
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
BAFF, APRIL and their receptors: Structure, function and signaling
Bossen, C., & Schneider, P. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.04.006 · Cited by 521
Alcohollike liver disease in nonalcoholics
Diehl, A. M., Goodman, Z., & Ishak, K. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90183-7 · Cited by 483
Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., & George, J. (2002) · Hepatology · doi:10.1053/jhep.2002.34738 · Cited by 362
B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling
Mackay, F., Silveira, P. A., & Brink, R. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.008 · Cited by 284
Teramoto, T., Sasaki, J., Ueshima, H., Egusa, G., Kinoshita, M., Shimamoto, K., Daida, H., Biro, S., Hirobe, K., Funahashi, T., et al. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.45 · Cited by 266
[The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)].
Saruta, T. (2005) · PubMed · Cited by 259
Monocyte Chemotactic Protein–1 As A Chemoattractant for Human Hepatic Stellate Cells
Marra, F., Romanelli, R. G., Giannini, C., Failli, P., Pastacaldi, S., Arrighi, M. C., Pinzani, M., Laffi, G., Montalto, P., & Gentilini, P. (1999) · Hepatology · doi:10.1002/hep.510290107 · Cited by 259
Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region?
FARRELL, G. C. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02989.x · Cited by 235
Teramoto, T., Sasaki, J., Ueshima, H., Egusa, G., Kinoshita, M., Shimamoto, K., Daida, H., Biro, S., Hirobe, K., Funahashi, T., et al. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e537 · Cited by 228
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease
Angulo, P., Alba, L. M., Petrovic, L. M., Adams, L. A., Lindor, K. D., & Jensen, M. D. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.020 · Cited by 197
Pathogenesis of Non-alcoholic Steatohepatitis: Human Data
Edmison, J., & McCullough, A. J. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.011 · Cited by 193
Appropriateness of Liver Biopsy
Poynard, T., Ratziu, V., & Bedossa, P. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/107982 · Cited by 192
Natural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis
Day, C. P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.041 · Cited by 176
Diagnostic Criteria for Dyslipidemia
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.17152 · Cited by 167
HIROOKA, M., KUMAGI, T., KUROSE, K., NAKANISHI, S., MICHITAKA, K., MATSUURA, B., HORIIKE, N., & ONJI, M. (2005) · Internal Medicine · doi:10.2169/internalmedicine.44.794 · Cited by 165
Self-citationTsochatzis, E. A., Papatheodoridis, G. V., & Archimandritis, A. J. (2009) · Mediators of Inflammation · doi:10.1155/2009/831670 · Cited by 141
Baranova, A. V., Gowder, S., Schlauch, K. A., Elariny, H. A., Collantes, R. S., Afendy, A., Ong, J. P., Goodman, Z. D., Chandhoke, V., & Younossi, Z. M. (2006) · Obesity Surgery · doi:10.1381/096089206778392149 · Cited by 131
Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), Vuppalanchi, R., Gould, R. J., Wilson, L. A., Unalp-Arida, A., Cummings, O. W., Chalasani, N., & Kowdley, K. V. (2012) · Hepatology International · doi:10.1007/s12072-011-9277-8 · Cited by 111
Alexaki, V.-I., Notas, G., Pelekanou, V., Kampa, M., Valkanou, M., Theodoropoulos, P., Stathopoulos, E. N., Tsapis, A., & Castanas, E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901186 · Cited by 99
Lutchman, G. A., Promrat, K., Kleiner, D. E., Heller, T., Ghany, M. G., Yanovski, J. A., Liang, T. J., & Hoofnagle, J. H. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.05.005 · Cited by 94
Pelekanou, V., Kampa, M., Kafousi, M., Darivianaki, K., Sanidas, E. E., Tsiftsis, D. D. A., Stathopoulos, E. N., Tsapis, A., & Castanas, E. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-76 · Cited by 81
B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation
Kim, Y.-H., Choi, B.-H., Cheon, H.-G., & Do, M.-S. (2009) · Experimental and Molecular Medicine · doi:10.3858/emm.2009.41.3.024 · Cited by 77
Sasai, H., Sairenchi, T., Iso, H., Irie, F., Otaka, E., Tanaka, K., Ota, H., & Muto, T. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0230 · Cited by 53
B Cell‐Activating Factor Controls the Production of Adipokines and Induces Insulin Resistance
Hamada, M., Abe, M., Miyake, T., Kawasaki, K., Tada, F., Furukawa, S., Matsuura, B., Hiasa, Y., & Onji, M. (2011) · Obesity · doi:10.1038/oby.2011.165 · Cited by 49
Self-citationMiyake, T., Akbar, S. M. F., Yoshida, O., Chen, S., Hiasa, Y., Matsuura, B., Abe, M., & Onji, M. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0218-4 · Cited by 45
Self-citation
Cited by
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Metadata
- Authors
- Miyake, T., Abe, M., Tokumoto, Y., Hirooka, M., Furukawa, S., Kumagi, T., Hamada, M., Kawasaki, K., Tada, F., Ueda, T., Hiasa, Y., Matsuura, B., & Onji, M.
- Affiliations
- Ehime University (JP)
- Corresponding author
- Onji, Morikazu
- ORCID
- Venue
- Hepatology International
- Published
- 2012-02-09
- Volume
- 7
- Issue
- 2
- Pages
- 539-547
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- OpenAlex
- W1973245617
- Cited by
- 59
- References
- 49
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 2
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Hepatology International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23591014, 24590979)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- B-cell activating factor, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, simple steatosis, serum BAFF levels, liver fibrosis, hepatocyte ballooning, histological severity, adipokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.